Title:
CCR8 ANTIGEN BINDING UNIT AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/098888
Kind Code:
A1
Abstract:
Described here is are antibodies to CCR8 having enhanced binding, ligand blocking and antibody dependent cellular cytotoxicity. Also described is are methods of treating a cancer by targeting tumor infiltrating lymphocytes in a cancer patient using a formulation comprising a CCR8 antibody described above.
Inventors:
KANG LISHAN (CN)
LIU HONGSHUI (CN)
WANG LINA (CN)
YIN SHANG (CN)
LI SHOU (CN)
WAN BING (CN)
SHI WENHUA (CN)
CHEN MIN (CN)
DAI XINCHUAN (CN)
BELLOVIN DAVID (US)
ZHANG JING (US)
LIU HONGSHUI (CN)
WANG LINA (CN)
YIN SHANG (CN)
LI SHOU (CN)
WAN BING (CN)
SHI WENHUA (CN)
CHEN MIN (CN)
DAI XINCHUAN (CN)
BELLOVIN DAVID (US)
ZHANG JING (US)
Application Number:
PCT/CN2022/136276
Publication Date:
June 08, 2023
Filing Date:
December 02, 2022
Export Citation:
Assignee:
ZAI LAB SHANGHAI CO LTD (CN)
ZAI LAB US LLC (US)
ZAI LAB US LLC (US)
International Classes:
A61K39/395; C07K16/28; A61P35/00
Domestic Patent References:
| WO2007044756A2 | 2007-04-19 | |||
| WO2021152186A2 | 2021-08-05 | |||
| WO2021163064A2 | 2021-08-19 |
Foreign References:
| CN110835371A | 2020-02-25 | |||
| EP3903817A1 | 2021-11-03 | |||
| US20190092875A1 | 2019-03-28 |
Other References:
CAMPBELL JOSEPH R., MCDONALD BRYAN R., MESKO PAUL B., SIEMERS NATHAN O., SINGH PRITI B., SELBY MARK, SPROUL TIM W., KORMAN ALAN J.: "Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 81, no. 11, 1 June 2021 (2021-06-01), US, pages 2983 - 2994, XP055866698, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-20-3585
Attorney, Agent or Firm:
BEIJING CAIHE LAW FIRM (CN)
Download PDF: